drugset / Press release
Syndax and Merck to Collaborate on Immuno-Oncology Study Evaluating Entinostat in Combination with KEYTRUDA® (pembrolizumab) in Lung Cancer and Melanoma
2015-03-31 · Syndax Pharmaceuticals · original syndax.com ↗
Syndax and Merck to Collaborate on Immuno-Oncology Study Evaluating Entinostat in Combination with KEYTRUDA<font size="-1"><sup>®</sup></font> (pembrolizumab) in Lung Cancer and Melanoma
The release as fetched from its publisher. syndax.com ↗